Secondary prevention of cardioembolic stroke: Oldest and newest promises

Clinical and Experimental Hypertension

Volumn 28, Issue 3-4, 2006, Pages 413-420

  Corea, F ^a   Spinelli, M ^a   Tambasco, N ^b   Silvestrelli, G ^c   Parnetti, L ^c  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b Dipartimento di Neurologia e Neuroriabilitazione   (Italy)

^c UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Anticoagulant; Cardio envlolism; Mechanical devices secondary prevention

Indexed keywords

ACETYLSALICYLIC ACID; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; COUMARIN ANTICOAGULANT; MELAGATRAN; THROMBIN INHIBITOR; WARFARIN; XIMELAGATRAN;

AGE DISTRIBUTION; BLEEDING; CARDIOVERSION; CAROTID ARTERY; CAROTID ARTERY BIFURCATION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONFERENCE PAPER; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; HEART ATRIUM FIBRILLATION; HEART RATE; HUMAN; IMPLANT; INTERNAL CAROTID ARTERY; LONG TERM CARE; PACEMAKER; SINUS RHYTHM; STROKE; STROKE PATIENT; THROMBOEMBOLISM; TREATMENT FAILURE; TREATMENT OUTCOME; BLOOD VESSEL PROSTHESIS; BLOOD VESSEL TRANSPLANTATION; INSTRUMENTATION; PROSTHESIS; REVIEW;

ANTI-ARRHYTHMIA AGENTS; ANTICOAGULANTS; ATRIAL FIBRILLATION; BLOOD VESSEL PROSTHESIS; BLOOD VESSEL PROSTHESIS IMPLANTATION; CAROTID ARTERY, INTERNAL; CEREBROVASCULAR ACCIDENT; HUMANS; PROSTHESIS DESIGN; TREATMENT OUTCOME;

EID: 33746451370     PISSN: 10641963     EISSN: 15256006     Source Type: Journal    
DOI: 10.1080/10641960600549900     Document Type: Conference Paper

References (18)

1. Bornstein N, Corea F, Galllai V, Parnetti L. Heart-brain relationship: atrial fibrillation and stroke. Clin Exp Hypertens 2002; 24(7-8):493-499.
2. EAFT Study Group. Silent brain infarction in nonrheumatic atrial fibrillation. Neurology 1996; 46:159-165.
3. Ezekowitz MD, James KE, Nazarian SM, Davenport J, Broderick JP, Gupta SR, et al. Silent cerebral infarction in patients with nonrheumatic atrial fibrillation The Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. Circulation 1995; 92:2178-2182.
4. Feinberg WM, Seeger JF, Carmody RF, Anderson DC, Hart RG, Pearce LA. Epidemiologic features of asymptomatic cerebral infarction in patients with nonvalvular atrial fibrillation. Arch Int Med 1990; 150:2340-2344.
5. Savino K, Calisti MG, Magnante A, Panciarola R, Sardone MG, Corea F, Corea L. Utilità diagnostica ed implicazioni terapeutiche dell'ecografia transesofagea Risultati su 791 esami consecutivi. Farmaci 1997; 21(1):29-39.
6. Deplanque D, Corea F, Arquizan C, Parnetti L, Mas JL, Gallai V, Leys D. Stroke and atrial fibrillation: is stroke prevention treatment appropriate beforehand? SAFE I Study Investigators. Heart 1999; 82(5):563-569.
7. Deplanque D, Leys D, Parnetti L, Schmidt R, Ferro J, De Reuck J, et al. SAFE II Investigators Stroke prevention and atrial fibrillation: reasons leading to an inappropriate management Main results of the SAFE II study. Br J Clin Pharmacol 2004; 57(6):798-806.
8. Olsson SB; Executive Steering Committee on behalf of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 2003; 362(9397):1691-1698.
9. Halperin JL; Executive Steering Committee, SPORTIF III and V Study Investigators. Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V). Am Heart J 2003; 146(3):431-438.
10. Blackshear JL, Odell JA. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg 1996; 61:755-759.
11. Donnan GA, Dewey HM, Chambers BR. Warfarin for atrial fibrillation: the end of an era? Lancet Neurol 2004; 3(5):305-308.
12. Pappone C, Rosanio S, Augello G, Gallus G, Vicedomini G, Mazzone P, et al. Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillation: outcomes from a controlled nonrandomized long-term study. J Am Coll Cardiol 2003; 42(2):185-197.
13. Cooper HA, Bloomfield DA, Bush DE, Katcher MS, Rawlins M, Sacco JD, Chandler M; AFFIRM Investigators. Relation between achieved heart rate and outcomes in patients with atrial fibrillation (from the Atrial Fibrillation Follow-up Investigation of Rhythm Management [AFFIRM] Study). Am J Cardiol 2004; 93(10):1247-1253.
14. Hagens VE, Vermeulen KM, TenVergert EM, Van Veldhuisen DJ, Bosker HA, Kamp O, et al. For the RAte Control versus Electrical cardioversion for persistent atrial fibrillation study group.Rate control is more cost-effective than rhythm control for patients with persistent atrial fibrillation - results from the RAte Control versus Electrical cardioversion (RACE) study. Eur Heart J 2004; 25(17):1542-1549.
15. Grad Y, Vermani R, Nishri B, Lieber B B, Assaf Y, Schneiderman J, et al. A new permanent arterial filtration device for embolic stroke prevention- the diverter. Cerebr UASC Dis 2002; 13(suppl 3):48.
16. Grad Y, Nishri B, Tanne D, Lieber BB, Yodfat O. The diverter -embolic stroke prevention using a new permanent arterial filtration device. ASAIO 2002; 48(3):199.
17. Meier B, Palacios I, Windecker S, Rotter M, Cao QL, Keane D, et al. Transcatheter left atrial appendage occlusion with Amplatzer devices to obviate anticoagulation in patients with atrial fibrillation. Catheter Cardiovasc Interv 2003; 60(3):417-422.
18. Ostermayer S, Reschke M, Billinger K, Trepels T, Buschek F, Bayard Y, Sievert H. Percutaneous closure of the left atrial appendage. J Interv Cardiol 2003; 16(6):553-556.